Yang, Hong <br/><br/>
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.  [electronic resource] 

 -  Cancer research  Feb 2012 
 - 779-89 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-11-2941  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Area Under Curve<br/>Bevacizumab<br/>Blotting, Western<br/>Camptothecin--administration & dosage<br/>Capecitabine<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cetuximab<br/>Colorectal Neoplasms--drug therapy<br/>Deoxycytidine--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm--drug effects<br/>Erlotinib Hydrochloride<br/>Fluorouracil--administration & dosage<br/>HCT116 Cells<br/>HT29 Cells<br/>Humans<br/>Indoles--administration & dosage<br/>Irinotecan<br/>Kaplan-Meier Estimate<br/>Mice<br/>Mice, Nude<br/>Mitogen-Activated Protein Kinases--metabolism<br/>Mutation<br/>Phosphorylation--drug effects<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Quinazolines--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Vemurafenib<br/>Xenograft Model Antitumor Assays